Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 235.85B |
| Revenue (ttm) | 54.75B |
| Net Income (ttm) | 16.22B |
| Shares Out | n/a |
| EPS (ttm) | 6.44 |
| PE Ratio | 14.54 |
| Forward PE | 12.08 |
| Dividend | 2.86 (3.02%) |
| Ex-Dividend Date | Dec 15, 2025 |
| Volume | 1,161 |
| Average Volume | 5,532 |
| Open | 94.30 |
| Previous Close | 95.30 |
| Day's Range | 93.70 - 95.30 |
| 52-Week Range | 65.50 - 99.00 |
| Beta | 0.30 |
| RSI | 67.46 |
| Earnings Date | Feb 3, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Sandisk, Bloom Energy, And Oklo Are Among the Top 10 Large-Cap Gainers Last Week (Jan. 5-Jan. 9): Are the Others in Your Portfolio?
A powerful mix of defense spending, AI infrastructure deals and takeover speculation sent several large-cap stocks sharply higher last week, reshaping the market's leaderboard . These ten large-cap st...
The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips
The Dow Jones Industrial Average itself yields modestly, but the Dogs of the Dow 2026 pack more dividend bite. The index's top payers dish up to 6.8%.
Key deals this week: Merck, Glencore, CrowdStrike, Marvell Technology, Steel Dynamics and more
Notable analyst calls this week: Palantir, Merck and Lockheed Martin among top picks
January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its single share price. Analyst projections suggest the top ten Dow Dogs could delive...
Merck (MRK) Eyes Acquisition of Revolution Medicines (RVMD) for $30 Billion
Merck (MRK) Eyes Acquisition of Revolution Medicines (RVMD) for $30 Billion
Merck (MRK) Eyes $30 Billion Acquisition of Revolution Medicines
Merck (MRK) Eyes $30 Billion Acquisition of Revolution Medicines
Merck Reportedly in Talks to Acquire Revolution Medicines (RVMD)
Merck Reportedly in Talks to Acquire Revolution Medicines (RVMD)
Merck in talks to acquire Revolution Medicines for about $30B - WSJ
Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion
Revolution is developing drugs that target a molecular driver of cancers.
Trade Tracker: Kevin Simpson buys FedEx, SLB and sells a covered call on Merck
Kevin Simpson, founder and chief investment officer at Capital Wealth Planning , joins CNBC's "Halftime Report" to detail his latest portfolio moves.
Trade Tracker: Kevin Simpson buys FedEx, SLB and sells a covered call on Merck
Kevin Simpson, founder and chief investment officer at Capital Wealth Planning , joins CNBC's "Halftime Report" to detail his latest portfolio moves.
Healthy Returns: What to expect from pharma at the JPM conference
At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.
Merck in Talks to Buy Revolution Medicines Per Financial Times Report
Merck is in talks to acquire RVMD, which could bolster its oncology pipeline, according to a Financial Times report.
Merck (MRK) Considers Multi-Billion Dollar Acquisition of Revolution Medicines (RVMD)
Merck (MRK) Considers Multi-Billion Dollar Acquisition of Revolution Medicines (RVMD)
Merck Eyes Revolution Medicines in a Potential $32 Billion Deal
Merck Eyes Revolution Medicines in a Potential $32 Billion Deal
ClearBridge Dividend Strategy Fund adds PCG, RHHBY, exits EIX, MRK among Q4 moves
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
Pharmaceuticals giant Merck & Co. Inc. (NYSE: MRK) is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32 bi...
After-Hours Biotech Gainers: RVMD Soars On Merck Deal Talks Reports, SXTC, KALV, SGMT Rally
(RTTNews) - Several biotechnology and pharmaceutical companies posted notable gains in Thursday's after-hours trading session, driven by corporate updates, clinical milestones, and acquisition specula...
Merck urges science-led US vaccine schedule after CDC trims childhood vaccine list
Merck on Thursday said any changes to the U.S. child and adolescent immunization schedule should rest on comprehensive data and guidance from vaccine experts, after federal health officials shifted se...
Merck (MRK) Eyes Acquisition of Revolution Medicines (RVMD)
Merck (MRK) Eyes Acquisition of Revolution Medicines (RVMD)
Merck (MRK) Engages in Discussions with Competitor Firm
Merck (MRK) Engages in Discussions with Competitor Firm
Merck (MRK) Reportedly in Acquisition Discussions with Revolution Medicines
Merck (MRK) Reportedly in Acquisition Discussions with Revolution Medicines
Merck (MRK) Engages in Acquisition Talks with Revolution Medicines
Merck (MRK) Engages in Acquisition Talks with Revolution Medicines
Revolution Medicines soars on report Merck in talks to buy
Revolution Medicines (RVMD) stock jumped 5% after a report that Merck (MRK) is in talks to buy the cancer drugmaker.